인쇄하기
취소

Diabetes drug 'Actos' to be pulled from market because of risk of bladder cancer

Published: 2011-06-15 06:56:00
Updated: 2011-06-15 06:56:00
Japanese pharmaceutical company Takeda’s blockbuster anti-diabetes pill “Actos (pioglitazone)” faces being banned in the Korean market as the Korea Food and Drug Administration (KFDA) on Monday ordered doctors to refrain from prescribing it for type-2 diabetes patients due to bladder cancer risk.

Only when there are no alternative pills to be prescribed, according to the KFDA. However, give...

Fees

- Email service daily and homepage access.
  1. $300 per month.
  2. 5 Email holders per each company.
  3. Anual contract base.
Copyright Yakup.com All rights reserved.
약업닷컴의 모든 컨텐츠는 저작권법의 보호를 받습니다. 무단 전재⋅복사⋅배포 등을 금합니다.